Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu Pembrolizumab PET Imaging for In Vivo Expression of PD1
NCT04605614Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of 64Cu-DOTA-pembrolizumab in hematopoietic and lymphoid cell neoplasm and malignant solid neoplasm, sponsored by City of Hope. Primary endpoints: Incidence of adverse events up to 3 days and Dose limiting toxicity up to 3 days. Planned start Apr 2022; status: withdrawn.
02
Drugs
64Cu-DOTA-pembrolizumab
03
Conditions
hematopoietic and lymphoid cell neoplasmmalignant solid neoplasm
Beyond the preview
Go deeper on NCT04605614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605614.